Article Navigation

Journal Article

Cancer and Risk of COVID‐19 Through a General Community Survey

Author Notes

Abstract

Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID‐19) and adverse outcomes. However, evidence from large population‐based studies examining whether cancer and cancer‐related therapy exacerbates the risk of COVID‐19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID‐19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID‐19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2‐fold increased risk of a positive test. The association between cancer and COVID‐19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID‐19 infection and adverse outcomes.

Introduction

Individuals with cancer may be at higher risk for coronavirus disease 2019 (COVID‐19). However, much of the available data are limited to small studies conducted among hospitalized patients. Through a large community‐based survey, we sought to determine whether incidence of infection, including milder disease with more limited symptoms, is higher in individuals with cancer, including those on chemotherapy/immunotherapy.

Methods

We recruited individuals from the general population in the U.K., U.S., and Sweden using The COVID Symptom Study, a freely available smartphone application developed by Zoe Global Ltd. with scientific input from researchers and clinicians at Massachusetts General Hospital and King's College London. The application offers a guided interface to report a range of baseline demographic information and comorbidities, as previously reported [1]. Participants are encouraged to use the application daily to report symptoms and COVID‐19 testing results. We queried if individuals were living with cancer (yes/no) and if they were on chemotherapy or immunotherapy (yes/no) beginning on March 29, 2020. We used multivariable logistic regression models to examine the association between cancer and the risk of a positive COVID‐19 test, adjusting for age, date, country, and additional covariates including sex, body mass index (<18.5, 18.5–24.9, 25–29.9, and ≥30 kg/m²), history of diabetes, heart disease, lung disease, kidney disease, and current smoking status (each yes/no). We separately analyzed the risk associated with chemotherapy or immunotherapy for a positive COVID‐19 test among individuals with cancer. Two‐sided p values <.05 were considered statistically significant. All analyses were performed using R 3.6.1 (Vienna, Austria).

Results

Through May 8, 2020, 1,807,559 participants provided demographic and longitudinal symptom and testing information. Compared with individuals without cancer, those with cancer were older, more frequently male, and more commonly overweight or obese, among other comorbidities (Table 1). They were more likely to use several common medications and have health problems requiring them to stay at home. Among 23,266 individuals with cancer and 1,784,293 without cancer, we documented 155 and 10,249 reports of a positive COVID‐19 test, respectively (Table 2). Compared with individuals without cancer, those with cancer had a 60% increased risk of a positive COVID‐19 test (adjusted odds ratio [aOR]: 1.60; 95% confidence interval (CI): 1.36–1.88). The association between cancer and a positive COVID‐19 test was stronger among participants older than 65 years (aOR: 1.93; 95% CI: 1.51–2.46) compared with younger participants (aOR: 1.32; 95% CI: 1.06–1.64; P_interaction < .001) and among males (aOR: 1.71; 95% CI: 1.36–2.15) compared with females (aOR: 1.43; 95% CI: 1.14–1.79; P_interaction = .02). The risk estimates did not significantly differ according to race (white: aOR: 1.84; 95% CI: 1.52–2.23; nonwhite: aOR: 2.08; 95% CI: 1.05–4.12; P_interaction = .85). Additional adjustment for education and income as surrogates for socioeconomic status did not materially change the associations. Chemotherapy or immunotherapy was associated with a twofold increased risk of a positive COVID‐19 test (aOR: 2.22; 95% CI: 1.68–2.94). An increased risk of hospitalization due to COVID‐19 was associated with a cancer diagnosis (aOR: 2.47; 95% CI: 2.22–2.76) and chemotherapy/immunotherapy (aOR: 4.16; 95% CI: 2.50–4.95). Using a validated symptom‐based prediction model for COVID‐19 [2], the aOR for predicted COVID‐19 was 1.32 (95% CI: 1.22–1.42) for those with cancer and 1.55 (95% CI: 1.33–1.79) for those on chemotherapy/immunotherapy. The symptoms were somewhat less prominent in patients with cancer (data not shown).

Table 1

Open in new tab

Baseline characteristics of participants according to cancer history and chemotherapy or immunotherapy

Characteristics	Cancer, %		Chemotherapy/immunotherapy, %
Characteristics	No (n = 1,784,293)	Yes (n = 23,266)	No (n = 1,802,655)	Yes (n = 4,904)
Country
U.K.	81.6	77.1	81.5	75.1
U.S.	11.8	18.3	11.9	19.7
Sweden	6.6	4.7	6.6	5.2
Age group, years
<25	15.5	0.9	15.3	1.8
25–34	14.1	1.0	14.0	1.7
35–44	17.0	3.9	16.9	5.9
45–54	18.9	10.7	18.8	14.8
55–64	17.3	23.1	17.4	23.4
≥65	17.2	60.3	17.6	52.5
Male sex	42.7	55.2	42.9	45.8
Ethnicity
Hispanic	5.9	3.5	5.9	4.4
Non‐Hispanic	90.2	93.3	90.2	91.7
Prefer not to say	3.9	3.3	3.9	3.9
Race
White	93.6	95.6	93.7	94.9
Black	1.4	1.0	1.4	1.1
Asian	2.5	1.7	2.5	2.0
Other	2.0	1.2	2.0	1.4
Prefer not to say	0.4	0.4	0.4	0.5
Body mass index group
<18.5	6.5	3.3	6.4	4.1
18.5–24.9	40.4	37.0	40.3	38.7
25–29.9	31.1	36.5	31.2	33.8
≥30	22.0	23.2	22.0	23.3
Comorbidities
Diabetes	4.0	10.2	4.1	10.3
Heart disease	3.4	12.6	3.5	10.6
Lung disease	12.1	17.1	12.1	18.4
Kidney disease	0.8	4.5	0.9	4.8
Smoking status
Never	70.8	61.6	70.7	63.7
Past	20.2	33.2	20.4	31.4
Current	9.0	5.3	8.9	5.0
Limited mobility^a	7.1	40.9	7.4	64.1
Medication use
Immunosuppressants^b	3.5	16.3	3.5	43.7
ACE inhibitor	7.3	17.1	7.4	15.4
Aspirin	4.8	16.3	4.9	17.5
NSAIDs	7.4	10.8	7.5	10.8
Interaction with individuals with COVID‐19
No	87.0	93.2	87.1	94.5
Yes, suspected	9.5	4.8	9.4	3.8
Yes, documented	3.5	2.0	3.5	1.7
Frontline health care worker	7.2	2.8	7.1	2.1

Characteristics	Cancer, %		Chemotherapy/immunotherapy, %
Characteristics	No (n = 1,784,293)	Yes (n = 23,266)	No (n = 1,802,655)	Yes (n = 4,904)
Country
U.K.	81.6	77.1	81.5	75.1
U.S.	11.8	18.3	11.9	19.7
Sweden	6.6	4.7	6.6	5.2
Age group, years
<25	15.5	0.9	15.3	1.8
25–34	14.1	1.0	14.0	1.7
35–44	17.0	3.9	16.9	5.9
45–54	18.9	10.7	18.8	14.8
55–64	17.3	23.1	17.4	23.4
≥65	17.2	60.3	17.6	52.5
Male sex	42.7	55.2	42.9	45.8
Ethnicity
Hispanic	5.9	3.5	5.9	4.4
Non‐Hispanic	90.2	93.3	90.2	91.7
Prefer not to say	3.9	3.3	3.9	3.9
Race
White	93.6	95.6	93.7	94.9
Black	1.4	1.0	1.4	1.1
Asian	2.5	1.7	2.5	2.0
Other	2.0	1.2	2.0	1.4
Prefer not to say	0.4	0.4	0.4	0.5
Body mass index group
<18.5	6.5	3.3	6.4	4.1
18.5–24.9	40.4	37.0	40.3	38.7
25–29.9	31.1	36.5	31.2	33.8
≥30	22.0	23.2	22.0	23.3
Comorbidities
Diabetes	4.0	10.2	4.1	10.3
Heart disease	3.4	12.6	3.5	10.6
Lung disease	12.1	17.1	12.1	18.4
Kidney disease	0.8	4.5	0.9	4.8
Smoking status
Never	70.8	61.6	70.7	63.7
Past	20.2	33.2	20.4	31.4
Current	9.0	5.3	8.9	5.0
Limited mobility^a	7.1	40.9	7.4	64.1
Medication use
Immunosuppressants^b	3.5	16.3	3.5	43.7
ACE inhibitor	7.3	17.1	7.4	15.4
Aspirin	4.8	16.3	4.9	17.5
NSAIDs	7.4	10.8	7.5	10.8
Interaction with individuals with COVID‐19
No	87.0	93.2	87.1	94.5
Yes, suspected	9.5	4.8	9.4	3.8
Yes, documented	3.5	2.0	3.5	1.7
Frontline health care worker	7.2	2.8	7.1	2.1

Proportions are calculated based on the total number of participants with available data.

History of cancer, uses of aspirin and NSAIDs, and smoking status have been queried since launch in the U.S. and Sweden and since March 29, 2020, in the U.K.

^aImmunosuppressant medications including steroids, methotrexate, biologics were asked.

^bLimited mobility was asked as “In general, do you have any health problems that require you to stay at home?”

Abbreviations: ACE, angiotensin‐converting enzyme; COVID‐19, coronavirus disease 2019; NSAIDs, nonsteroidal anti‐inflammatory drugs.

Table 1

Open in new tab

Baseline characteristics of participants according to cancer history and chemotherapy or immunotherapy

Characteristics	Cancer, %		Chemotherapy/immunotherapy, %
Characteristics	No (n = 1,784,293)	Yes (n = 23,266)	No (n = 1,802,655)	Yes (n = 4,904)
Country
U.K.	81.6	77.1	81.5	75.1
U.S.	11.8	18.3	11.9	19.7
Sweden	6.6	4.7	6.6	5.2
Age group, years
<25	15.5	0.9	15.3	1.8
25–34	14.1	1.0	14.0	1.7
35–44	17.0	3.9	16.9	5.9
45–54	18.9	10.7	18.8	14.8
55–64	17.3	23.1	17.4	23.4
≥65	17.2	60.3	17.6	52.5
Male sex	42.7	55.2	42.9	45.8
Ethnicity
Hispanic	5.9	3.5	5.9	4.4
Non‐Hispanic	90.2	93.3	90.2	91.7
Prefer not to say	3.9	3.3	3.9	3.9
Race
White	93.6	95.6	93.7	94.9
Black	1.4	1.0	1.4	1.1
Asian	2.5	1.7	2.5	2.0
Other	2.0	1.2	2.0	1.4
Prefer not to say	0.4	0.4	0.4	0.5
Body mass index group
<18.5	6.5	3.3	6.4	4.1
18.5–24.9	40.4	37.0	40.3	38.7
25–29.9	31.1	36.5	31.2	33.8
≥30	22.0	23.2	22.0	23.3
Comorbidities
Diabetes	4.0	10.2	4.1	10.3
Heart disease	3.4	12.6	3.5	10.6
Lung disease	12.1	17.1	12.1	18.4
Kidney disease	0.8	4.5	0.9	4.8
Smoking status
Never	70.8	61.6	70.7	63.7
Past	20.2	33.2	20.4	31.4
Current	9.0	5.3	8.9	5.0
Limited mobility^a	7.1	40.9	7.4	64.1
Medication use
Immunosuppressants^b	3.5	16.3	3.5	43.7
ACE inhibitor	7.3	17.1	7.4	15.4
Aspirin	4.8	16.3	4.9	17.5
NSAIDs	7.4	10.8	7.5	10.8
Interaction with individuals with COVID‐19
No	87.0	93.2	87.1	94.5
Yes, suspected	9.5	4.8	9.4	3.8
Yes, documented	3.5	2.0	3.5	1.7
Frontline health care worker	7.2	2.8	7.1	2.1

Characteristics	Cancer, %		Chemotherapy/immunotherapy, %
Characteristics	No (n = 1,784,293)	Yes (n = 23,266)	No (n = 1,802,655)	Yes (n = 4,904)
Country
U.K.	81.6	77.1	81.5	75.1
U.S.	11.8	18.3	11.9	19.7
Sweden	6.6	4.7	6.6	5.2
Age group, years
<25	15.5	0.9	15.3	1.8
25–34	14.1	1.0	14.0	1.7
35–44	17.0	3.9	16.9	5.9
45–54	18.9	10.7	18.8	14.8
55–64	17.3	23.1	17.4	23.4
≥65	17.2	60.3	17.6	52.5
Male sex	42.7	55.2	42.9	45.8
Ethnicity
Hispanic	5.9	3.5	5.9	4.4
Non‐Hispanic	90.2	93.3	90.2	91.7
Prefer not to say	3.9	3.3	3.9	3.9
Race
White	93.6	95.6	93.7	94.9
Black	1.4	1.0	1.4	1.1
Asian	2.5	1.7	2.5	2.0
Other	2.0	1.2	2.0	1.4
Prefer not to say	0.4	0.4	0.4	0.5
Body mass index group
<18.5	6.5	3.3	6.4	4.1
18.5–24.9	40.4	37.0	40.3	38.7
25–29.9	31.1	36.5	31.2	33.8
≥30	22.0	23.2	22.0	23.3
Comorbidities
Diabetes	4.0	10.2	4.1	10.3
Heart disease	3.4	12.6	3.5	10.6
Lung disease	12.1	17.1	12.1	18.4
Kidney disease	0.8	4.5	0.9	4.8
Smoking status
Never	70.8	61.6	70.7	63.7
Past	20.2	33.2	20.4	31.4
Current	9.0	5.3	8.9	5.0
Limited mobility^a	7.1	40.9	7.4	64.1
Medication use
Immunosuppressants^b	3.5	16.3	3.5	43.7
ACE inhibitor	7.3	17.1	7.4	15.4
Aspirin	4.8	16.3	4.9	17.5
NSAIDs	7.4	10.8	7.5	10.8
Interaction with individuals with COVID‐19
No	87.0	93.2	87.1	94.5
Yes, suspected	9.5	4.8	9.4	3.8
Yes, documented	3.5	2.0	3.5	1.7
Frontline health care worker	7.2	2.8	7.1	2.1

Proportions are calculated based on the total number of participants with available data.

History of cancer, uses of aspirin and NSAIDs, and smoking status have been queried since launch in the U.S. and Sweden and since March 29, 2020, in the U.K.

^aImmunosuppressant medications including steroids, methotrexate, biologics were asked.

^bLimited mobility was asked as “In general, do you have any health problems that require you to stay at home?”

Abbreviations: ACE, angiotensin‐converting enzyme; COVID‐19, coronavirus disease 2019; NSAIDs, nonsteroidal anti‐inflammatory drugs.

Table 2

Open in new tab

Associations between cancer history, chemotherapy/immunotherapy, and risk of COVID‐19

COVID‐19/cancer status	Event/participants	Odds ratio (95% CI)
COVID‐19/cancer status	Event/participants	Model 1	Model 2
Positive COVID‐19 testing
Living with cancer
No	10,249/1,784,293	1	1
Yes	155/23,266	1.65 (1.40–1.93)	1.60 (1.36–1.88)
Chemotherapy/immunotherapy
No	4,854/1,802,655	1	1
Yes	50/4,904	2.34 (1.77–3.09)	2.22 (1.68–2.94)
Predicted COVID‐19 infection
Living with cancer
No	83,874/1,784,293	1	1
Yes	725/23,266	1.38 (1.27–1.48)	1.32 (1.22–1.42)
Chemotherapy/immunotherapy
No	84,403/1,802,655	1	1
Yes	196/4,904	1.61 (1.39–1.86)	1.55 (1.33–1.79)
Hospitalization for COVID‐19
Living with cancer
No	11,698/1,784,293	1	1
Yes	370/23,266	2.69 (2.42–2.99)	2.47 (2.22–2.76)
Chemotherapy/immunotherapy
No	11,928/1,802,655
Yes	140/4,904	4.62 (3.89–5.49)	4.16 (3.50–4.95)

COVID‐19/cancer status	Event/participants	Odds ratio (95% CI)
COVID‐19/cancer status	Event/participants	Model 1	Model 2
Positive COVID‐19 testing
Living with cancer
No	10,249/1,784,293	1	1
Yes	155/23,266	1.65 (1.40–1.93)	1.60 (1.36–1.88)
Chemotherapy/immunotherapy
No	4,854/1,802,655	1	1
Yes	50/4,904	2.34 (1.77–3.09)	2.22 (1.68–2.94)
Predicted COVID‐19 infection
Living with cancer
No	83,874/1,784,293	1	1
Yes	725/23,266	1.38 (1.27–1.48)	1.32 (1.22–1.42)
Chemotherapy/immunotherapy
No	84,403/1,802,655	1	1
Yes	196/4,904	1.61 (1.39–1.86)	1.55 (1.33–1.79)
Hospitalization for COVID‐19
Living with cancer
No	11,698/1,784,293	1	1
Yes	370/23,266	2.69 (2.42–2.99)	2.47 (2.22–2.76)
Chemotherapy/immunotherapy
No	11,928/1,802,655
Yes	140/4,904	4.62 (3.89–5.49)	4.16 (3.50–4.95)

Model 1: adjusted for age groups, country, and date at entry.

Model 2: further adjusted for body mass index (<18.5, 18.5–24.9, 25–29.9, and ≥ 30 kg/m²), sex, history of diabetes, heart disease, lung disease, kidney disease, and current smoker status.

Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019.

Table 2

Open in new tab

Associations between cancer history, chemotherapy/immunotherapy, and risk of COVID‐19

COVID‐19/cancer status	Event/participants	Odds ratio (95% CI)
COVID‐19/cancer status	Event/participants	Model 1	Model 2
Positive COVID‐19 testing
Living with cancer
No	10,249/1,784,293	1	1
Yes	155/23,266	1.65 (1.40–1.93)	1.60 (1.36–1.88)
Chemotherapy/immunotherapy
No	4,854/1,802,655	1	1
Yes	50/4,904	2.34 (1.77–3.09)	2.22 (1.68–2.94)
Predicted COVID‐19 infection
Living with cancer
No	83,874/1,784,293	1	1
Yes	725/23,266	1.38 (1.27–1.48)	1.32 (1.22–1.42)
Chemotherapy/immunotherapy
No	84,403/1,802,655	1	1
Yes	196/4,904	1.61 (1.39–1.86)	1.55 (1.33–1.79)
Hospitalization for COVID‐19
Living with cancer
No	11,698/1,784,293	1	1
Yes	370/23,266	2.69 (2.42–2.99)	2.47 (2.22–2.76)
Chemotherapy/immunotherapy
No	11,928/1,802,655
Yes	140/4,904	4.62 (3.89–5.49)	4.16 (3.50–4.95)

COVID‐19/cancer status	Event/participants	Odds ratio (95% CI)
COVID‐19/cancer status	Event/participants	Model 1	Model 2
Positive COVID‐19 testing
Living with cancer
No	10,249/1,784,293	1	1
Yes	155/23,266	1.65 (1.40–1.93)	1.60 (1.36–1.88)
Chemotherapy/immunotherapy
No	4,854/1,802,655	1	1
Yes	50/4,904	2.34 (1.77–3.09)	2.22 (1.68–2.94)
Predicted COVID‐19 infection
Living with cancer
No	83,874/1,784,293	1	1
Yes	725/23,266	1.38 (1.27–1.48)	1.32 (1.22–1.42)
Chemotherapy/immunotherapy
No	84,403/1,802,655	1	1
Yes	196/4,904	1.61 (1.39–1.86)	1.55 (1.33–1.79)
Hospitalization for COVID‐19
Living with cancer
No	11,698/1,784,293	1	1
Yes	370/23,266	2.69 (2.42–2.99)	2.47 (2.22–2.76)
Chemotherapy/immunotherapy
No	11,928/1,802,655
Yes	140/4,904	4.62 (3.89–5.49)	4.16 (3.50–4.95)

Model 1: adjusted for age groups, country, and date at entry.

Model 2: further adjusted for body mass index (<18.5, 18.5–24.9, 25–29.9, and ≥ 30 kg/m²), sex, history of diabetes, heart disease, lung disease, kidney disease, and current smoker status.

Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019.

Discussion

Among >1.8 million participants, we found that individuals living with cancer had a 60% increased risk of a positive COVID‐19 test or hospitalization with COVID‐19, with greater risks for older individuals or those receiving anticancer therapies. Prior studies have shown that individuals with cancer make up a disproportionate share of poorer COVID‐19 outcomes [3–6], including death. However, these studies had small sample sizes and are largely based on hospitalized patients, capturing the most severe cases. Individuals living with cancer also tend to be older with greater comorbidities that predispose to hospitalization and adverse events.

A retrospective cohort study with 1,035 COVID‐19–positive patients with cancer in the U.S., Canada, and Spain reported high 30‐day all‐cause mortality [7]. This study also demonstrated numerically higher rates of death outside the intensive care unit in patients with active cancer, with the reverse pattern seen for those in remission. A prospective cohort study reported that COVID‐19 mortality in 800 U.K.‐based patients with cancer was principally related to advancing age and the presence of other noncancer comorbidities, but not recent anticancer treatment [8]. Our results from a large, community‐based sample support that incidence of infection, including milder disease with more limited symptoms, is also higher in individuals with cancer.

Our study was limited by the use of self‐reported information collected from individuals who used smartphone devices, thereby under‐representing those without smartphones. COVID‐19 testing was not based on uniform screening. However, shortages of polymerase chain reaction–based testing kits in both the U.K. and the U.S. early in the pandemic did not make such an approach feasible. Additionally, we had limited data on specific tumor types and treatment regimen. We are planning future studies collecting more detailed information from individuals with cancer with linkage to other data sources.

Conclusion

Within a large population‐based sample that encompassed more than 20,000 patients with cancer, we demonstrated a significantly increased risk of COVID‐19 infection among patients with cancer, which was greater among older and male individuals. Treatment with chemotherapy or immunotherapy was associated with increased risk of infection.

Acknowledgments

We thank the more than 3 million contributing citizen scientists who have downloaded the COVID Symptom Study, including participants of cohort studies within the COronavirus Pandemic Epidemiology (COPE) Consortium. We also thank the investigators of the cohort studies enrolled in the COPE Consortium; the MGH Clinical and Translational Epidemiology Unit Clinical Research Coordination team; Sophie Papa, Paul Nathan, and Heather Shaw for development of cancer‐related questions; the staff of Zoe Global Ltd for providing technical support for the app; and Stand Up to Cancer for their assistance in media and social media outreach. Zoe provided in‐kind support for all aspects of building, running, and supporting the app and service to all users worldwide. King's College of London investigators (K.A.L., C.J.S., T.D.S.) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), and the Alzheimer's Society (AS‐JF‐17‐011). K.A.L. was supported by the Seerave Foundation. A.T.C. is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz also supported MGH investigators (W.M., D.R.S., D.A.D., L.H.N., C.G.G., A.D.J., S.K., C.H.L., R.M., M.S., A.T.C.). Support was also received from the Swedish Foundation for Strategic Research (LUDC‐IRC 15‐0067), the Swedish Heart‐Lung Foundation, and the Swedish research Council. In the U.K., the App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS‐19/20‐18210, and all subscribers provided consent. In the U.S, ethics approval was provided by the Human Research Committee at Mass General Brigham. In Sweden, ethics approval for the study was provided by the central ethics committee (DNR 2020‐01803). Data collected in the app are being shared with other health researchers through the NHS‐funded Health Data Research U.K. (HDRUK)/SAIL consortium, housed in the U.K. Secure e‐Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483‐9cdc‐41b2‐b82c‐14ee3dd705f6). U.S. investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope‐consortium). Data updates can be found at https://covid.joinzoe.com.

Disclosures

David A. Drew: Zoe Global Ltd. (RF); Jonathan Wolf: Zoe Global Ltd. (E, OI); Tim D. Spector: Zoe Global Ltd. (C/A); Andrew T. Chan: Zoe Global Ltd. (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

References

Drew

Nguyen

Steves

et al.

Rapid implementation of mobile technology for real‐time epidemiology of COVID‐19

Science

2020

;

368

1362

–

1367

Menni

Valdes

Freidin

et al.

Real‐time tracking of self‐reported symptoms to predict potential COVID‐19

Nat Med

2020

;

1037

–

1040

Dai

Liu

et al.

Patients with cancer appear more vulnerable to SARS‐CoV‐2: A multicenter study during the COVID‐19 outbreak

Cancer Discov

2020

;

783

–

791

Google Scholar

PubMed

OpenURL Placeholder Text

WorldCat

Liang

Guan

Chen

et al.

Cancer patients in SARS‐CoV‐2 infection: A nationwide analysis in China

Lancet Oncol

2020

;

335

–

337

Miyashita

Mikami

Chopra

et al.

Do patients with cancer have a poorer prognosis of COVID‐19? An experience in New York City

Ann Oncol

2020

;

1088

–

1089

Robilotti

Babady

Mead

et al.

Determinants of COVID‐19 disease severity in patients with cancer

Nat Med

2020

;

1218

–

1223

Kuderer

Choueiri

Shah

et al.

Clinical impact of COVID‐19 on patients with cancer (CCC19): A cohort study

Lancet

2020

;

395

1907

–

1918

Lee

LYW

Cazier

Starkey

et al.

COVID‐19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study

Lancet

2020

;

395

1919

–

1926

Author notes

†

Contributed equally

Disclosures of potential conflicts of interest may be found at the end of this article.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]

Download all slides

Views

4,535

Altmetric

Total Views 4,535

2,270 Pageviews

2,265 PDF Downloads

Since 12/1/2021

Month:	Total Views:
December 2021	95
January 2022	215
February 2022	206
March 2022	234
April 2022	173
May 2022	213
June 2022	160
July 2022	152
August 2022	156
September 2022	203
October 2022	230
November 2022	147
December 2022	152
January 2023	186
February 2023	151
March 2023	166
April 2023	111
May 2023	138
June 2023	129
July 2023	91
August 2023	117
September 2023	114
October 2023	123
November 2023	105
December 2023	45
January 2024	56
February 2024	51
March 2024	91
April 2024	78
May 2024	53
June 2024	31
July 2024	38
August 2024	42
September 2024	44
October 2024	41
November 2024	44
December 2024	17
January 2025	28
February 2025	19
March 2025	46
April 2025	34
May 2025	10

Article Contents

Cancer and Risk of COVID‐19 Through a General Community Survey

Abstract

Introduction

Methods

Results

Discussion

Conclusion

Acknowledgments

Disclosures

References

Author notes

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

Article Contents

Cancer and Risk of COVID‐19 Through a General Community Survey Open Access

Abstract

Introduction

Methods

Results

Discussion

Conclusion

Acknowledgments

Disclosures

References

Author notes

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

This Feature Is Available To Subscribers Only

Cancer and Risk of COVID‐19 Through a General Community Survey